Does therapeutic reference pricing always result in cost-containment? The Hungarian evidence.
Therapeutic reference pricing is one of the potential cost containment methods for pharmaceuticals. The most critical question of reference pricing is how to select reference product(s) if their efficacy is different, especially if different strengths of the same substance are available. Authors describe the Hungarian experience related to the introduction of therapeutic reference pricing for statin therapies as of 1 September 2003. The National Health Insurance Fund selected the reference products based on their low price per DDD. Therapeutic reference pricing was expected to reduce the expenditure on statins by switching therapy to cheaper alternatives and therefore decreasing the average price per prescribed unit. The National Health Insurance Fund expected price erosion not only for branded products directly affected by generics but even for patented ones. Despite generic price erosion of simvastatin, the average unit price of statins was reduced by only 3% at 7 months after the introduction of the reference pricing system. During the same period the average DDD per prescription was increased from 1.14 to 1.65. The price of patented statins did not change over this period. Introduction of therapeutic reference pricing neglected evidence-based medicine results and ultimately increased the expenditure on statins in Hungary. Selection of the cheapest DDD per unit as the reference product resulted in growth of DDD per prescription, and consequently increased price per prescribed unit of statins. The failure of the system could have been even more dramatic if increased utilisation of generic statins had not reduced the negative effect of therapeutic reference pricing. Based upon the first experiences of the Hungarian implementation, the method described in this paper for the extension of generic reference pricing to therapeutic categories is not justifiable.
Kaló
Zoltán
Z
Novartis Hungary Ltd, Budapest, Hungary. zoltan.kalo@novartis.com
Muszbek
Noémi
N
Bodrogi
József
J
Bidló
Judit
J
D003363:Cost Control; D016527:Drug Costs; D019317:Evidence-Based Medicine; D006801:Humans; D006814:Hungary; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000191:economics* / Q000493:pharmacokinetics*; D007009:Hypolipoproteinemias / Q000188:drug therapy; D013810:Therapeutic Equivalency
D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors